Formulary Forum: Ixabepilone: A New Antimitotic for the Treatment of Metastatic Breast Cancer

Abstract

Spanish

French

Objective:

To evaluate the safety and efficacy of ixabepilone as a new antimitotic chemotherapeutic agent for the treatment of breast cancer.

Data Sources:

Data were identified by searches of MEDLINE, PubMed, and American Society of Clinical Oncology abstracts from 1966 to March 2008, using the primary search terms ixabepilone, epothilones, BMS-247550, and breast cancer.

Study Selection And Data Extraction:

Phase 1, Phase 2, and Phase 3 clinical trials examining the safely and efficacy of ixabepilone and its place in cancer treatment were reviewed. Preference was given to large Phase 2 and 3 clinical trials in the breast cancer population. Manufacturer product information was used to supplement data lacking in published trials.

Data Synthesis:

Ixabepilone belongs to a novel class of drugs, the epothilones, which are nontaxano microtubule-stabilizing agents. Ixabepilone, in combination with capecitabine, has been approved by the Food and Drug Administration for treatment in patients with metastatic or locally advanced breast cancer that progresses after anthracycline and taxane therapy, or in patients with taxane-resistant cancer with contraindication to further anthracycline therapy. Ixabepilone has also been approved as monotherapy in patients with metastatic and locally advanced breast cancer refractory to taxanes, anthracyclines, and capecitabine. The most common adverse reactions reported by 20% or more of the patients receiving ixabepilone were peripheral sensory neuropathy, fatigue/asthenia, myalgia/arthralgia, alopecia, nausea, vomiting, stomatitis/mucositis, diarrhea, and musculoskeletal pain. The most common hematologic abnormalities seen in more than 40% of the patients include neutropenia, leukopenia, anemia, and thrombocytopenia. Premedication with histamine H₁ and H₂ antagonists is recommended to prevent hypersensitivity reactions.

Conclusions:

Based on the clinical trials reviewed here and the current information available, ixabepilone is a welcome addition to the options available for the treatment of patients with metastatic breast cancer refractory to standard therapy.

Keywords

BMS-247550 breast cancer epothilones ixabepilone

Get full access to this article

View all access options for this article.

References

Bollag

, McQueney

, Zhu

. Epothilones, a new class of microtubule stabilizing agent with a taxol-like mechanism of action. Cancer Res 1995;55:2325–33.

Nettles

, Li

, Cornett

. The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography. Science 2004;305:866–9.

Product information. Ixempra (ixabepilone). New York: Bristol-Myers Squibb, October 2007.

Sparreboom

, van Zuylen

, Brouwer

. Cremophor EL–mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999;59:1454–7.

Shimizu

, Yamamoto

, Yamada

. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother Pharmacol 2008;61:751–8. Epub 27 Jun 2007.

Aghajanian

, Burris

, Jones

. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 2007;25:1082–8.

Dickson

, Peck

, Wu

, Burns

Ixabepilone given weekly in patients with advanced malignancies: final efficacy and safety results of a phase I trial (abstract 2040). ASCO Annual Meeting Proceedings Part 1. 2006;24(suppl):18S.

Zhuang

, Agrawal

, Edgerly

. A phase 1 clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 2005;103:1932–8.

Abraham

, Agrawal

, Bakke

. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003;21:1866–73.

10.

Hensley

, Dizon

, Derosa

. A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Invest New Drugs 2007;25:335–41.

11.

Therasse

, Arbuck

, Eisenhauer

. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.

12.

Low

, Wedam

, Lee

. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005;23:2726–34.

13.

Roché

, Yelle

, Cognetti

. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:3415–20.

14.

Perez

, Lerzo

, Pivot

. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407–14.

15.

Denduluri

, Low

, Lee

. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007;25:3421–7.

16.

Galsky

, Small

, Oh

. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23:1439–46.

17.

Hussain

, Tangen

, Lara

. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005;23:8724–9.

18.

Vansteenkiste

, Lara

, Le Chevalier

. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007;25:3448–55.

19.

Whitehead

, McCoy

, Rivkin

. A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs 2006;24:515–20.

20.

Thomas

, Gomez

, Li

. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210–7.

21.

Rosenberg

, Galsky

, Rohs

. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second-line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer 2006;106:58–62.

22.

Szebeni

, Muggia

, Alving

. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998;90:300–6.

23.

Windebank

, Blexrud

, de Groen

. Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther 1994;268:1051–6.

24.

Cardinal Health. www.cardinal.com (accessed 2008 Jul 14).

25.

Roche

, Perez

, Llombart-Cussac

. Ixabepilone, an epothilone B analog, is effective in ER, PR, HER-2 negative (triple negative) patients (pts): data from neoadjuvant and metastatic breast cancer (MBC) trials (abstract 256P). Ann Oncol 2006;17:S9.

26.

Sessa

, Perotti

, Lladò

. Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. Ann Oncol 2007;18:1548–53.

27.

Mok

, Choi

, Yau

. Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study. Oncology 2006;71:292–6.

28.

Rubin

, Rothermel

, Tesfaye

. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 2005;23:9120–9.

29.

Beer

, Higano

, Saleh

. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs 2007;25:565–70.

30.

Cortes

, Baselga

Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 2007;12:271–80.

31.

Klar

, Buchmann

, Schwede

, Skuballa

, Hoffmann

, Lichtner

Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl 2006;45:7942–8.